46brooklyn Research

The Pharmacy Business Model Is Breaking. States Are Scrambling To Fix It The crisis may be much broader than just independent pharmacies. The business of community pharmacy as a whole is under duress.

White House expands TrumpRx with three new drugs The platform offers discounts on more than 50 brand-name prescription drugs, though many of them have cheaper generic equivalents available.

“I think TrumpRx could be not a cure for the problems that exist today, but maybe it could supplant the system that we have.”

TrumpRx isn't doing much for drug prices. What would it take to change that? So far, IVF drugs and GLP-1s have been the site's most commonly searched medications, representing a tiny fraction of the prescription drugs Americans take.

“Drug prices are skyrocketing!” 🚀

“Drug prices are the lowest they’ve ever been!” 📉

Let’s cut through the noise by looking at the actual numbers.

Our latest at 46brooklyn.com

46brooklyn's Antonio Ciaccia joins The Patti Vasquez Show for a discussion on drug pricing and PBMs

Driving It Home with Patti Vasquez | January 29, 2026 Podcast Episode · Driving It Home with Patti Vasquez (Full Episodes) · 01/30/2026 · 1h 33m

“Independent analyses by 46brooklyn Research consistently show that multi-source generics have very low acquisition costs, while insured ‘negotiated prices’ are often an order of magnitude higher due to PBM pricing structures.”

When Insurance Stops Being Insurance: Medicare, UnitedHealth, and the Generic Drug Illusion My recent deep dive into Medicare drug pricing did not begin with pharmacy benefit managers or generic medications.

"Meaningful reform will require coordinated action across the entire healthcare ecosystem. This means all stakeholders, not just insurers. As part of this effort, lawmakers and policymakers must come to grips with core elements of systemwide dysfunctionality."

Surge In ACA Premiums Symptom Of Healthcare System In Need Of Reform If a political debate takes place this year on the topic of ACA cost containment and the affordability of premiums, it’s hoped that reform initiatives won’t be piecemeal.

“Resetting the relationship between list and net prices will make prescription drugs more affordable for patients, while triggering significant shifts in the business models of pharmacies, wholesalers, PBMs, and manufacturers.”

Drug Channels

2025 year in review and an early look at 2026 list price hikes and cuts

Our latest:

2026 drug pricing reload: Out with the old, in with the new — 46brooklyn Research Drug prices at the end of 2025, and the start of 2026 As a non-profit, we at 46brooklyn have made it our goal to provide insights into U.S. drug pricing data available in the public domain. We do this by gathering data from often forgotten government websites or from tables of data that do not lend

"Our government continues to apply band-aids to a bloated pricing system rather than prescribing real, system-wide solutions."

2026: A Tough Road Ahead in Health Care Americans are facing a flashing red-alert warning in health care — thanks to soaring costs and vanishing coverage – pushing the country toward what feels like the prelude to the 2008 financial crash.

Quick hit from NPR on our updated brand drug list price tracking:

Many brand-name drug prices are going up, despite Trump administration deals Every January, pharmaceutical companies increase the prices of hundreds of drugs. This year there's a disconnect between the deals with the Trump administration on some drug prices versus others.

"The biggest lie in all of healthcare is that PBMs negotiate lower prices. They don’t. What they do is sell access to their formularies." - Mark Cuban

Session Highlights from AVBCC’s 2025 Educational Summit & Program • Session Highlights from AVBCC’s 2025 Educational Summit & Program As the oncology landscape continues to evolve, concerns around rising costs, shifting legislation, and the rapid pace of technological innovation remain front and center for both consumers and organizations. Against this backdrop, A...